MUC1 and neoplasm: Future studies should explore whether combining anti-MUC1 antibodies with CD24 or CD47 blocking mAbs, for instance, which inhibit the “don’t eat me” signal on tumor cells, could further increase ADCP and ADCT as has been shown for HER2- and CD20-expressing cells upon administration of their respective targeting antibodies [17,62,63].